Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

At Northwestern Medicine, we put our patients first in an effort to deliver the best cancer care. Our teams of experts are here to help support patients and their caregivers during all stages of their cancer journey: diagnosis, treatment, and recovery.

Northwestern Medicine’s cancer centers provide access to state-of-the art therapies and comprehensive cancer care offering leading-edge medical, surgical and radiation oncology treatment options, as well as access to specialized research, clinical trials and diagnostic services.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is proud to be ranked as one of the top 8 cancer programs in the country by U.S. News & World Report.

Latest from Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine

Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

July 23, 2024

Video

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 08, 2024

Article

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Dr Gordon on the FDA Approval of Liso-Cel in Relapsed/Refractory MCL

May 30, 2024

Video

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival

May 16, 2024

Article

Seeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.

California Doctor Receives Northwestern Medicine’s First Combined Lung-Liver Transplant for Advanced Lung Cancer

April 16, 2024

Article

Gary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.

Closing Thoughts on the MDS Treatment Landscape

March 26, 2024

Video

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Takeaways from ASH 2023 in Higher-Risk MDS

March 19, 2024

Video

Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.

Updates from ASH 2023 in Higher-Risk MDS

March 19, 2024

Video

Hematologist-oncologists review clinical trial data updates presented at ASH 2023 in higher-risk MDS.

Patients With Cancer in Alabama 'Being Robbed of the Choice to Build a Family After Treatment'

March 13, 2024

Article

A consequence of the Alabama Supreme Court’s in vitro fertilization ruling is an unacceptably high risk of infertility for patients with cancer.

Treatment Options and Unmet Needs in Higher-Risk MDS

March 12, 2024

Video

Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.

Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

March 12, 2024

Video

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

March 05, 2024

Video

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

IMerge: Imetelstat in Patients With Lower-Risk MDS

March 05, 2024

Video

The expert panel discusses abstracts surrounding the IMerge clinical trial on imetelstat in patients with lower-risk myelodysplastic syndromes.

Outsmarting Chemo-Resistant Ovarian Cancer

February 28, 2024

Article

Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer—its hunger for cholesterol.

Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

February 27, 2024

Video

Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.

Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

February 27, 2024

Video

Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.